Condition: Advanced Hematologic Malignancies · Sponsor: Sumitomo Pharma America, Inc.
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
This description comes directly from the study's public registry record.
Holly Beever · 774-405-5261 · holly.beever@us.sumitomo-pharma.com
Always discuss trial participation with your own doctor first.
| University of North Carolina | Chapel Hill, North Carolina, United States | Not Yet Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07444268